摘要
多数卵巢癌患者就诊时即为晚期,故死亡率较高。化疗是晚期卵巢癌的主要治疗方法之一。紫杉醇/顺铂或卡铂静脉化疗已成为晚期卵巢癌一线治疗方案,使其疗效及预后有一定程度改善。腹腔化疗、淋巴管灌注化疗、动脉化疗及高剂量化疗等的临床研究进展,为晚期卵巢癌治疗提供多种途径。
出处
《国外医学(妇产科学分册)》
2003年第5期322-325,共4页
Foreign Medical Sciences(Obstet Gynecol Fascicle)
参考文献20
-
1de Jongh FE, van Veen RN, Veltman S J, et al. Weekly high-dose cisplatin is a feasible treament option: analysis on prognotic factors for toxicity in 400 patients. BJC, 2003, 88(8):1199-1206.
-
2Eltabbakh GH, Piver MS, Hempling RE, et al. Prolonged disease-free survival by maintenance chemotherapy among patients with recurrent platinum-sensitive ovarian cancer. Gynecol Oncol, 1998, 7(2):190-195.
-
3Umesaki N, Tanaka T, Muso H, et al. Intermittent cisplatin therapy for stage Ⅲ ovarian cancer patients following clinical remission. Gynecol Obstet Invest, 1999, 47{2):139-143.
-
4Piccart MJ, Green JA, Lacave AJ,et al. Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancerA randomized phase Ⅱ study of the European Organization for Researchand Treatment of Cancer Gynecology Group. J Clin Oncol, 2000, 18(6):1193-1202.
-
5Piccart M J, Bertelsen K, James K, et al .Bandomized intergroup trial of cisplatin-paelitaxel versus cisplatin-cyclophosphamide in woman with advanced epithelial ovarian cancer. J Natl Cancer Inst, 2000, 92(9): 699-708.
-
6Neijt JP, Engelholm SA, Tuxen MIL et al. Exploratory phase Ⅲ study of paclitaxel and cisplatin venus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol, 2000, 18(17):3084-3092.
-
7Yamamoto R, Minobe S, Kaneuchi M, et al. A phase Ⅰ/Ⅱ study of carboplatin and paclitaxel in patients with epithelial ovarian cancer. Jpn J Clin Oncol,2002, 32(4):128-134.
-
8Covens A, Carey M, Bryson P, et al. Systematic review of first-line chemotherapy for newly diagnosed postoperative patients with stage Ⅱ,Ⅲ, or Ⅳ epithelial ovarian cancer. Gynecol Oncol, 2002,85(1):71-80.
-
9Papadimitriou CA, Moulopoulos LA,Vlahos G, et al. Paclitaxel,cisplatin,and epirubicin first-line chemotherapy in stage Ⅲ and Ⅳ ovarian carcinoma long-term results of a phase Ⅱ study. Cancer,2000, 89(7):1547-1554.
-
10Kaye SB, Scottish Gynaecological Cancer Trials Group. The integration of docetaxel into flint-line chemotherapy for ovarian cancer. Int J Gynecol Cancer, 2001, 11 [Suppl 1]:31-33.
同被引文献11
-
1王建.紫杉醇联合顺铂治疗晚期卵巢癌30例[J].肿瘤防治杂志,2004,11(11):1228-1228. 被引量:2
-
2任婕,赵厚育.紫杉醇、顺铂联合化疗在晚期卵巢上皮性癌的应用[J].实用妇产科杂志,2005,21(5):293-294. 被引量:4
-
3Mliedzinska maciejewska M, Wcislo G. Mechanism of multidrug resistance of ovarian cancer[J]. Prxegl Lek, 2002,59: 854-858.
-
4Piccart M J, Bertelsen K,Jamas K, et al. Randomized intergroup trial of cisplatin-paclitaxel versus cispiantin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year resuits[J]. J Natl Cancer Inst, 2000,92(9):699-708.
-
5Ansquer Y, Le Blanc E. Clough K,et al. Neoadjuvant chemotherapy for unresectable ovarian carcinoma: a French multicenter study[J]. Cancer,2001,91(12):2329-2334.
-
6Mliedzinska maciejewska M, Wciso G. Mechanism of multidrug resistance of ovarian cancer[ J ]. Prxegl Lek ,2002,59 (2) : 854 - 858.
-
7Piccart M J, Bertesen K, Jamas K, et al. Randomized intergroup trial of cisplatin-paclitaxel versus cispiantin-cyclophospharnide in women with advanced epithelial ovarian cancer:three-year results[ J]. J Natl Cancer Inst,2000,92 (9) :699 - 708.
-
8Ansquer Y, Le-blanc E, Clough K, et al. Neoadjuvant chemotherapy for unrespectable ovarian earcinoma:a French multicenter study [ J ]. Canc- er,2001,91 (12) :2329 -2334.
-
9Goldberg JM, Piver MS, Hemplong RE, et al. Paditaxel and cisolatin combination chemotherapy in recarrent epithclial ovariar cancer[ J]. Gy- necol Oncol, 1996,63 ( 3 ) : 312 - 317.
-
10徐秀萍,张菊,施秀梅.卵巢癌患者运用紫杉醇联合顺铂化疗的护理[J].当代护士(中旬刊),2010,17(12):37-38. 被引量:3
引证文献2
-
1安云婷,李汉萍,罗兵,李隆玉,舒宽勇,邓克华,潘玫.紫杉醇联合铂类治疗晚期卵巢癌疗效观察[J].肿瘤防治杂志,2005,12(22):1759-1760. 被引量:13
-
2钟莉.紫杉醇联合顺铂化疗治疗卵巢癌82例临床观察及护理[J].临床合理用药杂志,2012,5(16):61-62. 被引量:6
二级引证文献19
-
1温雯静,刘晓东.伊立替康联用氧化苦参碱对卵巢癌的临床疗效[J].中国药物经济学,2013,8(S1):256-257. 被引量:1
-
2谢诚,钱美英,缪丽燕.MTT法测定肿瘤细胞药物敏感性与临床用药[J].药学与临床研究,2007,15(5):393-395. 被引量:15
-
3王爱云,常俊丽,李丽娜.紫杉醇联合顺铂治疗晚期卵巢癌20例的护理[J].中国误诊学杂志,2008,8(35):8758-8758. 被引量:3
-
4苏安,潘战和,张靖,王馨,吕霞,肖莉,王琳.伊立替康单药和联合沙利度胺治疗铂类耐药卵巢癌疗效比较观察[J].中华肿瘤防治杂志,2009,16(7):553-554. 被引量:9
-
5周宇.卡铂3周联合紫杉醇每周给药治疗复发卵巢癌37例临床观察[J].山东医药,2010,50(8):56-57. 被引量:8
-
6殷娟,郭俊,权瑞泉,尹振录,康助习,谢正强.伊立替康联合顺铂治疗复发转移性卵巢癌[J].现代肿瘤医学,2011,19(1):136-137. 被引量:4
-
7常青,王淑伟.紫杉醇联合顺铂不同给药途径治疗卵巢癌的疗效比较[J].肿瘤基础与临床,2011,24(3):211-212. 被引量:13
-
8曾涛,杨振宇,章蕴毅.进口与国产紫杉醇治疗卵巢恶性肿瘤的疗效和药物经济学评价[J].中国临床药学杂志,2011,20(5):266-270. 被引量:4
-
9常青,王淑伟.伊立替康单药与伊立替康联合顺铂二线治疗卵巢癌的疗效比较[J].吉林医学,2011,32(32):6822-6823. 被引量:10
-
10赵灵琴.脂质体阿霉素治疗晚期复发性卵巢癌的临床观察[J].海峡药学,2012,24(10):200-201. 被引量:2
-
1赵冰,王建生,任宏.多西紫杉醇/顺铂/5-氟脲嘧啶新辅助化疗方案治疗局部进展期胃癌的临床研究[J].消化外科,2004,3(2):90-92. 被引量:2
-
2DavidJ.加速超分割放疗,并行紫杉醇/顺铂化疗结合手术治疗Ⅲ期非小细胞肺癌[J].结核病与胸部肿瘤,2002(3):223-223.
-
3王海荣,周强,董华琼,刘黎.紫杉醇/顺铂联合同步放疗治疗晚期非小细胞肺癌的疗效[J].中国实用医药,2010,5(19):9-10.
-
4王晓华,刘黎,周强,王海荣,罗中银,刘睿.三维适形放疗同步联合紫杉醇/顺铂治疗局部晚期非小细胞肺癌的临床研究[J].西部医学,2012,24(9):1714-1715. 被引量:25
-
5娄云峰.多西紫杉醇/顺铂化疗同步放疗对局部晚期非小细胞肺癌疗效观察[J].中国医学工程,2013,21(8):11-11. 被引量:1
-
6王庆才,毛一香,陈凯,朱春荣,殷红.多西紫杉醇/顺铂/5-氟脲嘧啶联合治疗进展期胃癌的近期疗效观察[J].苏州大学学报(医学版),2008,28(3):477-479. 被引量:5
-
7刘丽霞,李国平,买宁.多西紫杉醇/顺铂化疗同步放疗对局部晚期非小细胞肺癌的疗效观察[J].中国医药指南,2013,11(4):479-480.
-
8周强,刘黎,王晓华,董华琼,王海荣,罗中银,刘睿,谭鹏,曹遂.三维适形放疗联合TP方案治疗Ⅳ期非小细胞肺癌的近期疗效观察[J].肿瘤预防与治疗,2013,26(6):336-339. 被引量:5
-
9贾正飞,冯永,仲琴,夏晓天.多西紫杉醇/顺铂化疗同步放疗对局部晚期非小细胞肺癌疗效观察[J].山东大学学报(医学版),2008,46(9):898-900. 被引量:7
-
10周勤芬,鲍正娟,张锐,谢滟.miRNA-200家族与晚期卵巢癌化疗疗效和预后的关系[J].现代妇产科进展,2016,25(3):178-181. 被引量:5